Evidence map›Paper›PMID 41795668›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

A novel eye-tracking digital marker outperforms plasma biomarkers in detecting cognitive impairment.

Yi Ling, Pan Sun, Chen Wang, Guoping Peng, Yiying Wang, Xin Zhou, Zhengbo He, Binhui Liu, Jie Zhang, Jie Yu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yi LingDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Pan SunInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China.
Chen WangSchool of Information Engineering, Hangzhou Medical College, Hangzhou, China.
Guoping PengDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yiying WangInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China.
Xin ZhouInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China.
Zhengbo HeInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China.
Binhui LiuInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China.
Jie ZhangCenter for Rehabilitation Medicine, Rehabilitation & Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
Jie YuDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yujie SuDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Kai LiSchool of Information Engineering, Hangzhou Medical College, Hangzhou, China.
Tengfei GuoInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China.ORCID 0000-0003-2982-0865
Benyan LuoDepartment of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Funding

Guangdong Basic and Applied Basic Science Foundation for Distinguished Young Scholars 2023B1515020113Medical and Health Science and Technology Project of Zhejiang Province 2022KY067the Fundamental Research for the Central Universities 2025ZFJH01the Key Research and Development Program of Zhejiang 2022C03064the National Natural Science Foundation of China 82171197the National Natural Science Foundation of China 82371484the National Natural Science Foundation of China 82422027the National Natural Science Foundation of China U24A20340
6 · The paper itself

Abstract

introductionDetecting and monitoring cognitive performance in older adults is critical. In this study, we evaluated the validity of an eye-tracking tool in diagnosing cognitive impairment.

methodsWe recruited 119 cognitively unimpaired (CU) individuals and 157 cognitively impaired (CI) patients who completed digital eye-tracking tests and cognitive scales. Of them, 154, 120, 53, and 146 underwent plasma biomarker tests, amyloid-β positron emission tomography (Aβ-PET) scans, tau-PET scans, and magnetic resonance imaging (MRI) scans. The diagnostic performance of eye-tracking markers and their relationships to Alzheimer's disease biomarkers and cognition were examined.

resultsThe eye-tracking panel exhibited better performance (area under the curve [AUC] = 0.865) in classifying CI from CU compared to plasma Aβ DISCUSSION: These findings demonstrate the validity of digital eye-tracking markers for screening patients with cognitive impairment, providing a novel digital marker for detecting cognitive decline in older adults.

Indexed as

BiomarkersCognitive DysfunctionEye-Tracking TechnologyAgedAged, 80 and overAmyloid beta-PeptidesFemaleHumansMagnetic Resonance ImagingMaleNeuropsychological TestsPeptide FragmentsPositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseasecognitive impairmentdigital biomarkereye‐trackingplasma biomarker

Identifiers

PMID41795668
PMCPMC12967584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.